CANTATA EvaluatorSM for IBRX

Methodology  
© 2024 BreakoutWatch.com
New CE:  
Company Information
Symbol: IBRX
Company: ImmunityBio, Inc.
Company Description:
Stock is Optionable: No
SEC Filings Edgar Online
General Due Diligence and Earnings Date Info: Due Diligence
Exchange: NASDAQ
CANTATA Evaluation for 11/21/2024
CE Zone
(Methodology)
 Time- liness CET CEF CE* Industry Industry
Rank 		Industry
Score
3-3 0/2 5.23 / 7 5.9 / 11 11.13 /18 Biotechnology 80 / 215 71 / 100
*Excluding Timeliness points
Timeliness
Item Data Points Maximum
Possible
1
Currently listed on CwH, DB, HTF or SQZ watchlists
0 1
2
Broke out in last 5 days and within 5% of BoP
0 1
 
Total Timeliness Points
 0 2
CANTATA Evaluation Technical (CET)
Item Data Points Maximum
Possible
1 Price relative to 50 and 200 day moving averages; 50 day relative to 200 day moving average
Last Close: $ 4.875
50 dma $ 4.17
200 dma $ 5.24
1.86 3
2 Relative Strength Rank
RS 59
1.78 3
3 Rank in Industry
Rank in Industry 245
# of stocks in Industry 601
0.61 1
4 Price relative to 52 week high
% off 52 week high 53.7 %
0.14 1
5 Up/Down Ratio
Up/Down Ratio: 1.7
0.85 1
  Miscellaneous Technical Data (no points assigned)
Beta -0.430
PE (vs. S&P 500) -9999999999.990 (-496770988.57 x)
5yr PE low - high -9999999999.990 - 0
n/a n/a
  Total Technical Points (CET) 5.23 9
CANTATA Evaluation Fundamentals (CEF)
1 Quarter over Quarter Earnings Growth
09/30/24 -0.144 vs. -0.192 [ 25.00 %]
06/30/24 -0.200 vs. -0.320 [ 37.50 %]
03/31/24 -0.199 vs. -0.272 [ 26.84 %]
12/31/23 -0.349 vs. -0.268 [ -30.22 %]
1.00 1
2 Positive Quarterly Earnings 0.60 1
3 Quarterly Earnings Growth Acceleration 0.80 1
4 Year over Year Earnings Growth Rates
12/31/23 [ 0 %]    
12/31/22 [ 0 %]    
12/31/21 [ 0 %]    
12/31/20 [ 0 %]    
12/31/19 [ 0 %]    
0.00 1
5 Quarter over Quarter Sales Growth Rates
09/30/24 6.100 vs. 0.100 [ 6000 %]
06/30/24 1.000 vs. 0.000 [ 9900 %]
03/31/24 0.000 vs. 0.400 [ -100 %]
12/31/23 0.100 vs. 0.100 [ 0 %]
1.00 1
6 Quarterly Sales Growth Rate Acceleration 0.50 1
7 Forward Earnings Growth Rates
Est. EPS growth current Fiscal Yr to next 64.300 %
Est. EPS Growth Next Fiscal Yr to Following 573.300 %
1.00 1
8 Institutional Ownership
Number of Institutional Owners 231.000
Net shares purchased MRQ ('000)
Institutional Ownership Details  
0.50 1
9 Return on Equity (ROE)
ROE - TTM 0 %
0.00 1
10 Cash Flow:
Cash from operations MRQ
Earnings TTM 0
Cash from operations TTM
Cash flow above/below earnings TTM 0
0.50 1
11 Net Margins
12/31/23 -9999999999.990%
12/31/22 -9999999999.990%
12/31/21 -9999999999.990%
0.00 1
  Miscelleneous Fundamental Data (no points assigned)
Financial Overview
Long term debt to equity -135.500 %  
Current Fiscal Year End 12/31/25  
Yearly Sales ('000) 12/31/23 0.600
      12/31/22 0.200
      12/31/21 0.900
      12/31/20 0.600
      12/31/19 2.200
n/a n/a
  Total Fundamental Points (CEF) 5.90 11
  Total CANTATA Evaluation Points 11.13 20